Nov 27 (Reuters) - Outlook Therapeutics Inc OTLK.O:
OUTLOOK THERAPEUTICS® ANNOUNCES PRELIMINARY TOPLINE RESULTS OF NORSE EIGHT CLINICAL TRIAL
OUTLOOK THERAPEUTICS INC -ANTICIPATE RESUBMISSION OF BLA IN CALENDAR Q1 2025
OUTLOOK THERAPEUTICS INC - ONS-5010 DID NOT MEET NON-INFERIORITY ENDPOINT IN NORSE EIGHT TRIAL
OUTLOOK THERAPEUTICS INC - FINAL EFFICACY DATA EXPECTED IN JANUARY 2025
Source text: ID:nGNX8RHkkB
Further company coverage: OTLK.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
No relevant data is available
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."